Search

everythinglearnresearchcommunity

for

Search:↓

COVID-19 vaccines may rarely worsen hair loss in people with severe alopecia, but the benefits of vaccination still outweigh this risk.

Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.

Oral tofacitinib effectively regrows hair in children with alopecia areata without major side effects.

Baricitinib stops hair loss and promotes regrowth in alopecia areata.

JAK inhibitors offer new hope for treating severe alopecia areata.

Interleukin-15 can help hair growth and protect hair follicles.

Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.

Etrasimod is safe but not effective for severe alopecia areata, though it may help milder cases.

Hair specialists vary in testing for alopecia areata, highlighting the need for standard guidelines.

Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Blocking JAK3 signaling can reverse hair loss from alopecia areata.

Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.

Dexamethasone mini-pulse therapy is effective for alopecia areata but less effective for those with early onset or hypothyroidism.

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

Alopecia areata after COVID-19 vaccination is rare but important to recognize for timely treatment.

Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.

Treat alopecia areata with personalized plans, using corticosteroids for mild cases and Janus Kinase inhibitors for severe cases, while also offering psychological support.

Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Adolescents with abnormal uterine bleeding often have polycystic ovarian syndrome and insulin resistance.

People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.

Ophiasis mainly affects females, lasts longer, and has lower regrowth rates, with a new classification system helping predict treatment response.

Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.

High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.

Chronic refractory alopecia areata has more skin-resident memory T cells, and JAK inhibitors may help reduce them.

Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.

Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.

Improving education, insurance, and support can help scarring alopecia patients access better care.